New drug duo tested as last hope for tough head & neck cancers
NCT ID NCT03019003
Summary
This early-stage study tested a new combination of two drugs for people with advanced head and neck cancer that had gotten worse despite previous immunotherapy. The goal was to see if giving an oral drug (decitabine) along with an immune-boosting drug (durvalumab) was safe and could help the patient's own immune system better recognize and fight the cancer. It involved 13 participants to find the right dose and check for early signs of effectiveness.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEAD AND NECK CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Massachusetts General Hospital
Boston, Massachusetts, 02114, United States
Conditions
Explore the condition pages connected to this study.